Sphinganine-1-phosphate protects kidney and liver after hepatic ischemia and reperfusion in mice through S1P1 receptor activation.
Liver failure due to ischemia and reperfusion (IR) and subsequent acute kidney injury are significant clinical problems. We showed previously that liver IR selectively reduced plasma sphinganine-1-phosphate levels without affecting sphingosine-1-phosphate (S1P) levels. Furthermore, exogenous sphinganine-1-phosphate protected against both liver and kidney injury induced by liver IR. In this study, we elucidated the signaling mechanisms of sphinganine-1-phosphate-mediated renal and hepatic protection. A selective S1P(1) receptor antagonist blocked the hepatic and renal protective effects of sphinganine-1-phosphate, whereas a selective S1P(2) or S1P(3) receptor antagonist was without effect. Moreover, a selective S1P(1) receptor agonist, SEW-2871, provided similar degree of liver and kidney protection compared with sphinganine-1-phosphate. Furthermore, in vivo gene knockdown of S1P(1) receptors with small interfering RNA abolished the hepatic and renal protective effects of sphinganine-1-phosphate. In contrast to sphinganine-1-phosphate, S1P's hepatic protection was enhanced with an S1P(3) receptor antagonist. Inhibition of extracellular signal-regulated kinase, Akt or pertussis toxin-sensitive G-proteins blocked sphinganine-1-phosphate-mediated liver and kidney protection in vivo. Taken together, our results show that sphinganine-1-phosphate provided renal and hepatic protection after liver IR injury in mice through selective activation of S1P(1) receptors and pertussis toxin-sensitive G-proteins with subsequent activation of ERK and Akt.
Park
Sang Won
SW
Department of Anesthesiology, College of Physicians and Surgeons of Columbia University, New York, NY 10032-3784, USA.
Kim
Mihwa
M
Chen
Sean W C
SW
Brown
Kevin M
KM
D'Agati
Vivette D
VD
Lee
H Thomas
HT
D058186:Acute Kidney Injury; D000818:Animals; D048049:Extracellular Signal-Regulated MAP Kinases / Q000494:pharmacology; D007511:Ischemia; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008107:Liver Diseases / Q000517:prevention & control*; D008246:Lysophospholipids; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D020928:Mitogen-Activated Protein Kinases / Q000494:pharmacology; D010069:Oxadiazoles; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D049349:Receptors, Lysosphingolipid / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D015427:Reperfusion Injury / Q000517:prevention & control*; D015398:Signal Transduction / Q000187:drug effects; D013110:Sphingosine / Q000031:analogs & derivatives / Q000494:pharmacology; D013876:Thiophenes
D008246:Lysophospholipids; D010069:Oxadiazoles; D049349:Receptors, Lysosphingolipid; C503964:SEW2871; D013876:Thiophenes; C060504:dihydrosphingosine 1-phosphate; C060506:sphingosine 1-phosphate; D051057:Proto-Oncogene Proteins c-akt; D048049:Extracellular Signal-Regulated MAP Kinases; D020928:Mitogen-Activated Protein Kinases; D013110:Sphingosine
J Cell Sci. 2005 Oct 15;118(Pt 20):4605-12
16219683
Exp Mol Pathol. 2003 Apr;74(2):86-93
12710939
Kidney Int. 2006 May;69(9):1601-8
16572108
Cardiovasc Res. 2009 May 1;82(2):212-20
19233865
Br J Pharmacol. 2004 Jul;142(5):851-60
15197107
Am J Surg. 2001 Feb;181(2):160-6
11425059
FASEB J. 1999 Nov;13(14):2061-70
10544189
Nat Cell Biol. 2000 Sep;2(9):645-52
10980706
Thromb Haemost. 2008 Jul;100(1):119-26
18612546
Kidney Int. 2007 Jun;71(12):1223-31
17377506
IUBMB Life. 2001 Dec;52(6):303-7
11895079
Scand J Clin Lab Invest. 1965;17(4):381-7
5838275
Cancer Res. 1996 Jan 15;56(2):273-9
8542580
Biochem Soc Symp. 1999;64:79-89
10207622
Am J Transplant. 2005 Jan;5(1):40-9
15636610
J Biol Chem. 2004 Apr 2;279(14):13839-48
14732717
Am J Transplant. 2002 Oct;2(9):843-9
12392290
Biochem J. 2006 Aug 1;397(3):461-71
16623665
Biochem Biophys Res Commun. 2006 Jul 21;346(1):293-300
16756949
Am J Physiol Renal Physiol. 2006 Jun;290(6):F1516-24
16403835
J Cell Biochem. 2004 Aug 1;92(5):882-99
15258913
J Am Soc Nephrol. 2004 Jan;15(1):102-11
14694162
Nat Chem Biol. 2006 Aug;2(8):434-41
16829954
Kidney Int. 2008 Jun;73(11):1220-30
18322542
Exp Cell Res. 2000 Apr 10;256(1):34-41
10739649
Br J Pharmacol. 2005 Oct;146(3):445-55
16086037
Cell Signal. 2006 Oct;18(10):1779-92
16529909
Methods. 2005 Feb;35(2):126-38
15649839
J Am Soc Nephrol. 2001 Feb;12(2):233-240
11158213
Mol Cell Biol. 1999 Aug;19(8):5800-10
10409766
Am J Physiol Renal Physiol. 2002 May;282(5):F844-52
11934694
J Med Chem. 2002 Oct 10;45(21):4629-38
12361389
Transplantation. 1993 Jun;55(6):1265-72
7685932
Exp Nephrol. 2002;10(5-6):383-92
12381923
Cell Stress Chaperones. 2001 Jan;6(1):49-58
11525243
Hum Mol Genet. 2002 May 1;11(9):1137-51
11978772
Kidney Int. 2009 Apr;75(8):809-23
19190680
Shock. 2010 Jan;33(1):31-42
19752779
Prog Nucleic Acid Res Mol Biol. 2002;71:493-511
12102559
Mol Cell Biol. 2002 Feb;22(3):816-34
11784858
Basic Res Cardiol. 2001 Apr;96(2):136-42
11327331
J Appl Physiol (1985). 2003 Mar;94(3):1193-203
12482769
J Biol Chem. 2004 Jul 9;279(28):29367-73
15138255
J Am Soc Nephrol. 2006 Nov;17(11):3115-23
16988058
J Biol Chem. 1999 Feb 19;274(8):4626-32
9988698
Am J Physiol. 1999 Jul;277(1):L159-66
10409243
Biochim Biophys Acta. 2006 Dec;1758(12):2016-26
16996023
Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H971-6
15358610
Cardiovasc Res. 2004 Aug 1;63(2):305-12
15249188
Psychopharmacology (Berl). 2003 Apr;166(4):366-72
12589527
Lab Invest. 2009 Feb;89(2):196-208
19079326
Liver Transpl. 2002 Feb;8(2):91-109
11862584
Am J Physiol Renal Physiol. 2007 Dec;293(6):F1847-57
17928414